Evidence map›Paper›PMID 32991669›Full record

ArticleThe Journal of experimental medicine2021

Helicobacter pylori metabolites exacerbate gastritis through C-type lectin receptors.

Masahiro Nagata, Kenji Toyonaga, Eri Ishikawa, Shojiro Haji, Nobuyuki Okahashi, Masatomo Takahashi, Yoshihiro Izumi, Akihiro Imamura, Koichi Takato, Hideharu Ishida and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Annals of medicine · 2026
    Review
  3. [Molecular mechanisms of chronic gastric mucosal inflammation induced byZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  4. Review
  5. Review
  6. Progress in immunotherapy forFrontiers in cellular and infection microbiology · 2026
    Review
  7. The association of the advanced lung cancer inflammation index with the risk ofFrontiers in cellular and infection microbiology · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Dysregulated macrophage immunity inFrontiers in immunology · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Effect ofFrontiers in oncology · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 5 countries.

Masahiro NagataDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Kenji ToyonagaDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Eri IshikawaDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Shojiro HajiDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Nobuyuki OkahashiDepartment of Bioinformatics Engineering, Graduate School of Information Science and Technology, Osaka University, Suita, Osaka, Japan.
Masatomo TakahashiDivision of Metabolomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka, Japan.
Yoshihiro IzumiDivision of Metabolomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka, Japan.
Akihiro ImamuraDepartment of Applied Bioorganic Chemistry, Gifu University, Gifu, Gifu, Japan.
Koichi TakatoDepartment of Applied Bioorganic Chemistry, Gifu University, Gifu, Gifu, Japan.
Hideharu IshidaDepartment of Applied Bioorganic Chemistry, Gifu University, Gifu, Gifu, Japan.
Shigenori NagaiDepartment of Molecular Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Petr IllarionovSchool of Biosciences, University of Birmingham, Birmingham, UK.
Bridget L StockerSchool of Chemical and Physical Sciences, Victoria University of Wellington, Wellington, New Zealand.
Mattie S M TimmerSchool of Chemical and Physical Sciences, Victoria University of Wellington, Wellington, New Zealand.
Dylan G M SmithSchool of Chemistry and Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, Parkville, Victoria, Australia.
Spencer J WilliamsSchool of Chemistry and Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, Parkville, Victoria, Australia.
Takeshi BambaDivision of Metabolomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka, Japan.
Tomofumi MiyamotoDepartment of Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.
Makoto AritaLaboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
Ben J AppelmelkMolecular Microbiology/Medical Microbiology and Infection Control, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Sho YamasakiDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Kyushu University · JPGifu University · JPThe University of Osaka · JPThe University of Melbourne · AUUniversity of Auckland · NZAmsterdam University Medical Centers · NLKeio University · JPRIKEN Center for Integrative Medical Sciences · JPTokyo Medical and Dental University · JPUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori causes gastritis, which has been attributed to the development of H. pylori-specific T cells during infection. However, the mechanism underlying innate immune detection leading to the priming of T cells is not fully understood, as H. pylori evades TLR detection. Here, we report that H. pylori metabolites modified from host cholesterol exacerbate gastritis through the interaction with C-type lectin receptors. Cholesteryl acyl α-glucoside (αCAG) and cholesteryl phosphatidyl α-glucoside (αCPG) were identified as noncanonical ligands for Mincle (Clec4e) and DCAR (Clec4b1). During chronic infection, H. pylori-specific T cell responses and gastritis were ameliorated in Mincle-deficient mice, although bacterial burdens remained unchanged. Furthermore, a mutant H. pylori strain lacking αCAG and αCPG exhibited an impaired ability to cause gastritis. Thus H. pylori-specific modification of host cholesterol plays a pathophysiological role that exacerbates gastric inflammation by triggering C-type lectin receptors.

Indexed as

AnimalsCholesterolChronic DiseaseGastritisHelicobacter InfectionsHelicobacter pyloriLectins, C-TypeMembrane ProteinsMiceMice, KnockoutReceptors, ImmunologicCholesterolClecsf8 protein, mousedendritic cell immunoactivating receptor, mouseLectins, C-TypeMembrane ProteinsReceptors, Immunologic

Identifiers

PMID32991669
PMCPMC7527975
OpenAlexW3090446835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.